Pharmaceutical Composition Comprising Brivaracetam And Lacosamide With Synergistic Anticonvulsant Effect
Patent No. EP2992891 (titled "Pharmaceutical Composition Comprising Brivaracetam And Lacosamide With Synergistic Anticonvulsant Effect") was filed by UCB Pharma on Jun 15, 2007. The application was issued on Aug 5, 2020.
Patent Summary
A pharmaceutical composition for preventing, alleviating, or treating epileptic seizures that contains a fixed ratio of lacosamide and another antiepileptic drug. The composition has a synergistic effect on seizure prevention compared to the drugs given alone. The fixed ratio is calculated based on the drugs' ED50 values. The composition can be administered as a fixed-dose combination or adjusted based on the fixed ratio multiples.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP2992891
- Application Number
- EP15156237A
- Filing Date
- Jun 15, 2007
- Status
- Granted And Under Opposition
- Jul 3, 2020
- Publication Date
- Aug 5, 2020
- External Links
- Slate, Register , Google Patents